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Abstract The association of hepatic steatosis with hepatic
insulin resistance and type 2 diabetes has prompted investi-
gators to elucidate the underlying mechanism. In this review
we focus on pathways of lipid metabolism, and we review
recent data, primarily from mouse models, that link lipid in-
termediates with insulin resistance. Most of the studies that
implicate acyl-CoA, lysophosphatidic acid, phosphatidic
acid, diacylglycerol, or ceramide rely on indirect associa-
tions. Convincing data to support the hypothesis that
specific lipid intermediates initiate pathways that alter insu-
lin signaling will require studies in which the concentration
of each purported signaling molecule can be manipulated
independently.—Nagle, C. A., E. L. Klett, and R. A.
Coleman. Hepatic triacylglycerol accumulation and insulin
resistance. J. Lipid Res. 2009. S74–S79.
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Nonalcoholic fatty liver disease (NAFLD) is character-
ized by excessive lipid accumulation in the liver in the
absence of ‘significant’ alcohol consumption and may
progress to nonalcoholic steatohepatitis, fibrosis, cirrhosis,
and hepatocellular carcinoma. In the United States, the
prevalence of NAFLD is estimated to be 20% (1); however,
the true prevalence of NAFLD is unknown because many
individuals in earlier stages of the disease are asymp-
tomatic and remain undiagnosed. Although NAFLD was
previously thought to be a benign condition, its develop-
ment parallels the development of the insulin resistance
(IR) syndrome and is associated with type 2 diabetes mel-
litus. Patients with the IR syndrome have a 4- to 11-fold in-
creased risk of developing NAFLD.
With overnutrition and lack of exercise, liver and other
tissues store excess energy as triacylglycerol (TAG). Shunt-
ing carbon-energy into a storage form is likely protective
against cytotoxic FA accumulation. Hepatic IR is asso-
ciated with the accumulation of TAG and FA metabolites
(fatty acyl-CoA, diacylglycerol (DAG), ceramide, and glyco-
sphingolipid). The short-term protection achieved from
sequestering FA may lead to long-term morbidity with
the development of further IR leading to type 2 diabetes
mellitus and the deterioration of hepatic function.
Although fatty liver correlates with hepatic IR, it remains
unclear whether IR or excess TAG stores develop first and
whether fatty liver invariably leads to IR. Peripheral IR may
cause fatty liver by elevating plasma FA, glucose, and insu-
lin, which stimulate hepatic lipid synthesis and impair he-
patic b-oxidation. However, high-fat feeding may cause
hepatic IR before systemic IR develops. We will focus on
the metabolic pathways involved in the development of
NAFLD, the role of altered hepatic TAG metabolism,
and the role of lipid metabolites in the development of IR.
METABOLIC PATHWAYS INVOLVED IN FATTY
LIVER DEVELOPMENT
Hepatic lipid accumulation can be caused by four differ-
ent metabolic perturbations: increased FA delivery to he-
patocytes from lipolyzed adipose TAG, dietary lipids, or
hepatic de novo lipogenesis (DNL); increased TAG syn-
thesis; decreased hepatic FA oxidation; and inadequate
TAG secretion in VLDL (Fig. 1).
Fatty acid delivery and synthesis
After consuming a meal containing fat, chylomicron-
TAG is delivered to the liver and is lipolyzed in lysosomes
with the release of FA. FA can also arise from DNL in re-
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sponse to a high carbohydrate meal, as excess glucose is
metabolized to acetyl-CoA, the major substrate for FA
synthesis. Malonyl-CoA, the product of acetyl-CoA car-
boxylase (ACC), is not only a substrate for FAS , but also
inhibits carnitine-palmitoyltransferase-1 (CPT-1), which
regulates long-chain FA entry into mitochondria for b-
oxidation. FAS sequentially adds two carbons from malonyl-
CoA to synthesize 16 and 18 carbon FA. These saturated
FAs must be activated by long-chain acyl-CoA synthetase
(ACSL) before they can be elongated by an elongase
(ELOVL6), desaturated by stearoyl-CoA desaturase (SCD),
or used for the synthesis of glycerolipids or cholesterol esters.
TAG synthesis
Hepatic FAs are derived from entering chylomicron
remnants, TAG lipolysis in lipid droplets, or DNL. After
activation, the acyl-CoAs enter the glycerolipid synthetic
pathway. In the liver, TAG may either be stored in cyto-
plasmic lipid droplets or incorporated into VLDL particles
and secreted into the blood. The four-step synthesis of
TAG, first identified by Eugene Kennedy and his col-
leagues (2), occurs on the cytosolic surface of the mitochon-
drial outer membrane and the endoplasmic reticulum.
Four glycerol-3-phosphate acyltransferases (GPAT), po-
tentially six 1-acylglycerol-3-phosphate acyltransferases
(AGPAT),1,2 three phosphatidic acid phosphatases (PAP),
and two DAG acyltransferases (DGAT) have been cloned3.
Hepatic TAG lipolysis and b-oxidation
During fasting, insulin levels fall, adipose TAG is hydro-
lyzed, and FAs are released and travel to the liver. It is not
clear whether exogenously derived FAs must first be rees-
terified and stored in lipid droplets before they can be oxi-
dized, or whether acyl-CoAs can be directly converted to
acyl-carnitines and enter the oxidative pathway. Within
the mitochondrial matrix, acyl-carnitines are converted
to acyl-CoAs by CPT-2. Very long chain acyl-CoA dehydro-
genase (VLCAD) acts on C12-C24 carbon acyl-CoAs, long
chain acyl-CoA dehydrogenase (LCAD) acts on C8-C20
acyl-CoAs, medium chain acyl-CoA dehydrogenase (MCAD)
acts on C4-C12 acyl-CoAs, and short-chain acyl-CoA de-
hydrogenase (SCAD) acts on C4-C6 acyl-CoAs. When the
tricarboxylic acid (TCA) cycle cannot metabolize all the
1 AGPAT8 and AGPAT6 are correctly termed GPAT3 and GPAT4,
respectively.
2 CGI-58, and endophilin both have AGPAT activity.
3 Several additional enzymes exhibit some DGAT activity, includ-
ing MGAT2.
Fig. 1. Pathways of FA and triacylglycerol metabolism. FAs used for triacylglycerol (TAG) synthesis or b-
oxidation are activated to form acyl-CoAs. If targeted toward b-oxidation, acyl-CoAs are converted to acyl-
carnitines, enter the mitochondria, and are metabolized by a succession of dehydrogenases that are relatively
specific for very-long (VLAD), long (LCAD), medium (MCAD), and short (SCAD) chain acyl-CoAs. The end-
product acetyl-CoA enters the tricarboxylic acid cycle (TCA), producing NADH and FADH, which contribute
to ATP formation by oxidative phosphorylation. When excess calories from glucose are available, acetyl-CoA
entering the TCA cycle is converted to citrate, which leaves the mitochondria and is used for FA synthesis via
acetyl-CoA carboxylase (ACC) and FAS. FA elongases (Elovl) and desaturases (SCD) modify acyl-CoAs, which
are used to esterify glycerol-3-phosphate by glycerol-3-P acyltransferases (GPAT). The lysophosphatidic acid
(LPA) product is esterified to form phosphatidic acid (PA) by an acyl-glycerol-3-P acyltransferase, the PA is
hydrolyzed by phosphatidic acid phosphohydrolase (PAP), and the final esterification step catalyzed by
diacylglycerol acyltransferase (DGAT) produces TAG. Liver TAG can be stored in lipid droplets or trans-
ferred to VLDL by the mitochondrial TAG transport protein.
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acetyl-CoA generated from b-oxidation, excess acetyl-CoA
is converted to ketone bodies.
VLDL secretion
The origin of VLDL-TAG remains poorly understood. A
precursor VLDL particle that contains apoB and a small
amount of TAG is formed in the endoplasmic reticulum
(ER). This small VLDL precursor may fuse within the ER
with a larger droplet of TAG to form a TAG-rich particle.
The TAG that fuses is thought to arise from cytosolic TAG
derived primarily from plasma FA uptake and less from
DNL (7). Incorporation of cytosolic TAG into VLDL may
require lipolysis and reesterification steps at the ER (3).
TRANSCRIPTIONAL REGULATION OF DE NOVO
LIPOGENESIS AND FA OXIDATION
An excess of glucose, FA, and insulin ultimately lead to
hepatic steatosis and worsening hepatic IR via a network of
transcription factors (Fig. 2). Activation of hepatic liver-X-
receptor (LXR) by endogenous oxysterol ligands results in
up-regulation of genes involved in cholesterol, lipid, and
bile acid metabolism. In mice, oral LXR agonists result
in enhanced hepatic FA synthesis, hepatic steatosis, and hy-
pertriglyceridemia, all mediated by increased expression
of SREBP-1c (4). Transgenic hepatic over-expression of
SREBP-1c produces a fatty liver and a 4-fold increase in
the rate of hepatic FA synthesis, with increases in lipogenic
genes like FAS, ACC and SCD-1 (5), and GPAT1 (5). In-
sulin increases LXRʼs ability to activate the SREBP-1c
promoter and increase hepatic lipogenesis (6). Thus, hy-
perinsulinemia can activate LXR and SREBP-1c and result
in increased lipogenesis, liver TAG accumulation, and wors-
ening hepatic IR.
ChREBP regulates hepatic lipid synthesis through tran-
scriptional control of the lipogenic genes ACC and FAS in
response to glucose (7). Liver-specific ChREBP inhibition
results in decreased hepatic lipogenesis and ameliorated
hepatic steatosis in ob/ob mice (7).
DO INTERMEDIATES IN THE KENNEDY PATHWAY
OF GLYCEROLIPID BIOSYNTHESIS INITIATE
SIGNALING PATHWAYS?
Although IR correlates highly with TAG content in skel-
etal muscle and liver, TAG itself is believed to be a surro-
gate marker for the true disruptor of the insulin signal,
variously hypothesized to be a) a cytokine released from
macrophages or adipocytes, b) activation of the NFkB path-
way (8), or c) a signaling pathway initiated by a FA-derived
Fig. 2. Altered insulin signaling by lipid intermediates. Increased nutrient influx raises intracellular FA con-
centrations. With nutrient surfeit, elevated malonyl-CoA inhibits CPT-1 and b-oxidation and results in in-
creased availability of acyl-CoAs for TAG synthesis and storage or secretion. Intermediates in the TAG
biosynthetic pathway activate inhibitors of insulin signaling, including protein kinase C (PKC), mTOR,
and S6K, which suppress IRS-1 activation of PIP3. Ceramide inhibits Akt-mediated insulin signaling, dere-
pressing FOXO and leading to increases in transcription of phosphoenolpyruvate (PEPCK) and glucose-
6-phosphatase (G-6-Pase). These enhance gluconeogenesis and hepatic glucose output. Nutrients act on
transcription factors (LXR, ChREBP, SREBP-1c and PPAR g), which increase transcription of genes involved
in FA and TAG synthesis (ACC, FAS, GPAT1). These enhance steatosis and hepatic insulin resistance. DHAP,
dihydroxyacetone-P; G3P, glycerol-3-P; GSK, glycogen synthase kinase.
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lipid. Lysophosphatidic acid (LPA), phosphatidic acid
(PA), and DAG are well-established initiators of signaling
pathways but have been studied primarily after their hydro-
lysis from membrane phospholipids. In liver, however, the
major production of LPA, PA, and DAG occurs via de novo
glycerolipid synthesis; lipid intermediates derived from this
pathway and related lipids [acyl-CoAs (9, 10), ceramide
(11) and acyl-carnitines] may also act as signaling mole-
cules. Because incubating cells with FA or infusing FA into
mice causes IR within a few hours, it appears that a direct
FA metabolite can promote IR.
BLOCK OF INSULIN SIGNALING BY
LIPID METABOLITES
With hepatic IR, insulin cannot effectively suppress he-
patic glucose output in a hyperinsulinemic-euglycemic
clamp study. IR can also be inferred by impaired tyrosine
phosphorylation of the insulin receptor and aberrant
phosphorylation of serine residues of insulin receptor sub-
strate-1 (IRS-1) and downstream members of the insulin
signaling pathway.
Our studies implicate GPAT1-produced DAG as a cause
of IR (12, 13); when excess DAG is formed, protein kinase
C (PKC)y is activated, and IRS-1 is phosphorylated on
Ser307, which suppresses IRS-1 tyrosine phosphorylation
and diminishes phosphatidylinositol 3-kinase activation.
These data suggest that the DAG formed during glycero-
lipid synthesis can interact with and activate PKC at distant
membranes and show that GPAT1 modulates the cell con-
tent of lipid intermediates. This is not entirely surprising
because lipogenic diets normally increase SREBP-1c-
mediated GPAT1 mRNA expression (2). In addition to
DAG, the glycerolipid intermediates LPA and PA can also
initiate signaling pathways. LPA is a ligand for peroxisome
proliferator-activated receptor (PPAR) g (14) and might
be responsible for the up-regulation of PPARg target genes
observed in NAFLD, whereas intracellular PA activates
mammalian target of rapamycin (15), which down-regulates
the insulin signal by promoting serine phosphorylation of
IRS when nutrients are present in excess.
THE ROLE OF LIPID METABOLITES IN THE
DEVELOPMENT OF HEPATIC INSULIN RESISTANCE
Although fatty liver is associated with IR, several rodent
models with steatosis remain insulin sensitive (16–21). Fac-
tors that may explain the variable relationship between fatty
liver and IR include the specific pathways that contribute to
hepatic fat accumulation, the type of lipid metabolites
that accumulate, the cellular location and FA composition
of those metabolites, the presence or absence of hepatic
or systemic inflammation, and the type of rodent diet used.
Altered de novo lipogenesis and glycerolipid synthesis
In humans with NAFLD, the estimated contribution of
adipose lipolysis, dietary FA, and hepatic DNL to hepatic
TAG and VLDL-TAG are 60%, 15%, and 24%, respectively
(22). It is not known, however, whether the lipid inter-
mediates derived from these pathways have similar effects
on the development of hepatic IR, or whether one path-
way predominates. When over-expression of hepatic LPL
increases FA flux into the liver from lipoproteins, hepatic
IR is associated with an increased hepatic content of TAG
and acyl-CoA (23). Augmented DNL also appears to be im-
portant, because ob/ob mice deficient in either SREBP-1c
or ChREBP are protected from hepatic steatosis and IR
(24, 25). Further, rodents with liver-specific decreases in
the synthesis of malonyl-CoA, ACC null mice, and rats that
over-express malonyl-CoA decarboxylase in liver have im-
proved hepatic insulin sensitivity due to lower DNL and
increased b-oxidation (26, 27). In contrast, mice with a
liver-specific knockout of FAS develop a fatty liver despite
suppressed DNL because PPARa is not activated (28). De-
spite the fatty liver that results from decreased b-oxidation,
FAS null mice have impaired gluconeogenesis and are
hypoglycemic and insulin sensitive.
Increased SREBP-1c activity in ob/ob mouse liver in-
creases GPAT1 mRNA expression and hepatic de novo glyc-
erolipid synthesis (29), whereas hepatic GPAT1 knockdown
in ob/ob mice lowers hepatic TAG and DAG content and
plasma glucose concentrations (30). Studies in GPAT1 knock
out (KO) mice and in rats with hepatic over-expression of
GPAT1 suggest that the lipid accumulation from de novo
glycerolipid synthesis contributes to the development of
hepatic IR in the absence of obesity or a high fat diet
(12, 13). Unlike lipid accumulation from DNL, hepatic
steatosis caused by a block in VLDL-TAG secretion does
not cause hepatic IR, perhaps because lipid intermediates
do not accumulate, suggesting that lipids destined for
VLDL secretion are in a separate cellular pool that cannot
affect inhibitors of insulin signaling (17).
Impaired b-oxidation
Obese mouse models largely demonstrate that activating
b-oxidation decreases hepatic lipid accumulation and im-
proves insulin sensitivity. For example, activating PPARa
with Wy-14,643 increases b-oxidation, reduces hepatic TAG
accumulation, and improves insulin signaling in ob/ob mice
and in lipoatrophic A-ZIP/F-1 mice (31, 32). However, the
role of suppressed b-oxidation in the development of IR is
less clear. Both prolonged fasting and short-term pharma-
cological inhibition of CPT-1 cause a fatty liver without IR
(18, 21). Unfortunately, DAG and other lipid intermedi-
ates were not measured in this study.
Fasting-induced steatosis
When hepatic TAG accumulates in lean fasted animals,
it does not cause hepatic IR. Perhaps signaling lipids are
sequestered in pools that cannot interfere with insulin sig-
naling. Similar to pharmacological inhibition of b-oxidation,
genetic deficiency of PPARa, VLCAD, or MCAD causes a
fatty liver and mild to severe hypoglycemia under fasting
conditions (33–35). PPARa KOmice are protected from he-
patic IR when fed a high fat (HF)-coconut oil diet (20), but
not when fed HF-palm oil or HF-lard diets (36). The insulin
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sensitivity of VLCAD and MCAD mice has not been studied,
but LCAD KO mice develop hepatic steatosis and reduced
FA oxidation without hypoglycemia (37). Although fasting
hepatic DAG and ceramide content do not differ between
wild-type (WT) and LCAD KO mice, the hepatic DAG con-
tent increases 3-fold in the LCAD KO livers after insulin
stimulation during a hyperinsulinemic-euglycemic clamp,
and is associated with hepatic IR (43). Thus, inhibiting
b-oxidation in fasted lean mice causes hepatic steatosis with-
out IR, whereas inhibiting b-oxidation in previously high-
fat-fed animals interferes with insulin signaling. Perhaps
impaired b-oxidation is most detrimental to insulin sensitiv-
ity when DNL is activated in response to feeding, thereby
resulting in increased synthesis of FA and glycerolipid inter-
mediates. It is not clear what makes one kind of lipid accu-
mulation differ from another, but differences in cellular
location or in lipid species may determine whether insulin
signaling is impaired. Additionally, none of these models de-
scribes a liver-specific inhibition of b-oxidation. Inhibiting
b-oxidation in adipose tissue or muscle may alter plasma cy-
tokine levels that secondarily improve or inhibit hepatic in-
sulin signaling.
Diet effects
Both DAG and ceramide can diminish hepatic insulin
sensitivity, and feeding rats a HF safflower oil diet (HF-SD)
for three days increases hepatic DAG and PKCy activity
and hepatic IR (10). Conversely, a liver-specific knock-down
of PKCy prevents HF-SD-induced hepatic IR, strength-
ening the hypothesis that PKCy and DAG mediate hepatic
IR in this model (38). Other mouse models that support
this hypothesis include hepatic over-expression of GPAT1
(13), LCAD KO mice (37), Elovl6 KO mice fed a high
fat-high sucrose diet (19), and mouse models fed with
the HF-SD including: ACC2 KO (19), ACC1 and 2 knock-
down (26), GPAT1 KO (12), and DGAT2 knockdown mice
(16). Although these studies provide strong evidence that
DAG and PKCy are important mediators of hepatic IR in
HF-SD fed animals, several studies question the impor-
tance of DAG. For example, GPAT1 KO mice are protected
from hepatic IR when fed the HF-SD, but not when fed a
diet high in saturated fat (39, 40). Similarly, mice treated
with DGAT2 ASO are protected from HF-SD IR, but not
from IR induced by a HF saturated diet (26, 41). These
discrepancies suggest that different fatty acid species affect
mechanisms of hepatic IR differently. For example, a HF-
lard diet causes a ceramide-associated hepatic IR that
is reversed by inhibiting sphingolipid synthesis, whereas
a HF-soy oil diet causes a DAG-associated IR that is not
affected by sphingolipid inhibition (11). Perhaps high-
saturated, but not high-unsaturated fat diets induce a
low-grade systemic inflammation. Increased macrophage
production of TNFa activates NFkB in hepatocytes and in-
creases ceramide and hepatic IR (8, 42). However, none of
the studies using a HF-SD to induce IR reported increases in
inflammation, so this diet may not be as proinflammatory as
diets high in saturated fat. Human diets consist of both sat-
urated and unsaturated fats, and DAG and ceramide may
both be relevant lipid mediators of IR in human NAFLD.
Elevated lipid intermediates without impaired
insulin sensitivity
Mice can have elevated hepatic TAG, DAG, and ceramide
without hepatic IR (16, 17). This discrepancy might be
explained if different pools of DAG and ceramide exist
within cells, with only certain pools able to regulate inhib-
itors of insulin signaling. Thus, measuring hepatic DAG
and ceramide total content instead of the content in spe-
cific membrane fractions may obscure the relevant mech-
anism. Additionally, some DAG and sphingolipid species
may be poor inhibitors of insulin signaling. The fact that
diets high in different FA species have remarkably different
effects on hepatic insulin sensitivity and gene expression
(11, 43) suggests that DAG FA composition could be rele-
vant. Further, ceramide-induced IR may be caused by gan-
glioside metabolites of ceramide (44). Future researchers
should measure not only gross lipid content, but also the
intracellular locations and FA composition of lipids, as well
as inflammatory markers that are associated with IR.
SUMMARY AND FUTURE DIRECTIONS
A major difficulty in assessing the importance or the sig-
nificance of any lipid intermediate to impaired insulin sig-
naling is the lack of direct experiments. Most of the studies
that implicate acyl-CoA, LPA, PA, DAG, or ceramide rely
on indirect associations. The effects of different diets are
not well documented or explained mechanistically, and
the inter-relationships between different putative signaling
pathways have been inadequately delineated. Convincing
data to support the hypothesis that specific lipid intermedi-
ates initiate signaling pathways that alter insulin signaling
may require additional studies in cultured hepatocytes in
which the concentration of each purported signaling mole-
cule can be manipulated independently.
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